India-based Glenmark Pharmaceuticals (NSE: GLENMARK) has been granted final approval by the US health regulator to market its generic version of Rythmol SR capsules, the company confirmed on Monday.
Rythmol SR capsules are indicated as an anti-arrhythmic medication, used in the treatment of illnesses whose symptoms include rapid heartbeats.
The US Food and Drug Administration (FDA) granted its approval for Propafenone Hydrochloride extended-release capsules USP, 225 mg, 325 mg and 425 mg.
Rythmol SR is a product of GlaxoSmithKline LLC.
The approval marks the company's 123rd product to gain approval for commercialisation in the US marketplace. It also has 63 Abbreviated New Drug Applications (ANDA) currently pending approval with the FDA.
Acurx wins US FDA's QIDP designation for ACX-362E for treating Clostridium difficile infection
Tenon Medical awarded US FDA's clearance for first patented single implant SIJ fusion system
New Study of Patients with Low-Risk PE Finds Xarelto Reduces Hospital Time, Decreases Costs
Spectra Medical Devices awarded US FDA approval to market single use 1% lidocaine ampule
Grifols wins new US FDA approval for the Procleix Ultrio Elite and Procleix WNV assays
Amphastar's Isoproterenol Hydrochloride Injection approved by FDA
First Generic Versions of Suboxone Sublingual Film Approved by FDA
Mylan unveils generic angiomax injection in 250 mg single-dose vial as an anticoagulant in the US
Mylan NV to launch Bivalirudin for Injection in US
Celltrion completes CT-P6 approval re-submission to US FDA
DreaMed Diabetes wins US FDA approval to market Advisor Pro in the type 1 diabetes digital market